Investment analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Eagle Pharmaceuticals Price Performance
NASDAQ:EGRX opened at $0.71 on Friday. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.81. The stock has a fifty day moving average of $1.21 and a 200 day moving average of $3.41.
Hedge Funds Weigh In On Eagle Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC grew its position in Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after acquiring an additional 25,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $971,000. RBF Capital LLC raised its holdings in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Eagle Pharmaceuticals in the 3rd quarter worth approximately $453,000. Institutional investors own 85.36% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
See Also
- Five stocks we like better than Eagle Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 11/25 – 11/29
- How to Read Stock Charts for Beginners
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
